ID   LAMA84-rn
AC   CVCL_DP54
DR   Wikidata; Q54901918
RX   PubMed=19047160;
CC   Selected for resistance to: ChEBI; CHEBI_52172; Nilotinib (AMN107; Tasigna).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0388 ! LAMA-84
SX   Female
AG   29Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 13
//
RX   PubMed=19047160; DOI=10.1158/0008-5472.CAN-08-1008;
RA   Mahon F.-X., Hayette S., Lagarde V., Belloc F., Turcq B., Nicolini F.,
RA   Belanger C., Manley P.W., Leroy C., Etienne G., Roche S.,
RA   Pasquet J.-M.;
RT   "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or
RT   Src kinase overexpression.";
RL   Cancer Res. 68:9809-9816(2008).
//